根据提交给美国证券交易委员会（SEC）的文件显示，生物技术公司Xilio Therapeutics Inc. 已与投资银行Leerink Partners LLC签订了一项普通股销售协议。
依据该协议，Xilio Therapeutics 可能通过“按市价”发行方式，不定期地发售和出售总价值最高达1722万美元的公司普通股。Leerink Partners将作为销售代理，负责相关股票的发售事宜。
此类融资安排为公司提供了灵活的资本募集渠道，使其能够根据市场条件和自身资金需求，适时地在公开市场出售股份以获取运营资金。此次潜在发售所得款项将用于公司一般企业用途，可能包括推进其肿瘤免疫疗法产品线的研发、临床试验以及其他运营开支。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.